RESUMEN
Axonal trauma leads to a series of pathologic events that can culminate in neuronal death. Although the precise mechanisms of retinal ganglion cell death after optic nerve crush in the rat model have not been elucidated, glutamate antagonists can protect retinal ganglion cells after optic nerve axotomy. We therefore explored whether a glutamate congener was toxic if applied directly within the optic nerve, or if toxicity depended upon an interaction at the cell body level. NMDA reduced retinal ganglion cell survival when applied directly into the rat optic nerve. Glutamate can be toxic if administered within the optic nerve; a direct effect at the cell body is not necessary. Future work will help to additionally unravel the steps by which axotomy induces excitotoxic damage to ganglion cells, and perhaps indicate protective interventions.
Asunto(s)
Agonistas de Aminoácidos Excitadores/toxicidad , N-Metilaspartato/toxicidad , Traumatismos del Nervio Óptico/veterinaria , Receptores de N-Metil-D-Aspartato/fisiología , Células Ganglionares de la Retina/fisiología , Animales , Axotomía/veterinaria , Supervivencia Celular/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Memantina/farmacología , Compresión Nerviosa , Nervio Óptico/efectos de los fármacos , Nervio Óptico/metabolismo , Traumatismos del Nervio Óptico/patología , Ratas , Ratas Long-Evans , Células Ganglionares de la Retina/efectos de los fármacosRESUMEN
Glaucoma is a leading cause of blindness worldwide and the second leading cause of irreversible blindness in the USA. The most common form of glaucoma, primary open angle glaucoma, is characterized by a chronically elevated intraocular pressure in the absence of any demonstrable structural abnormalities in the eye. The pathologic hallmark of glaucomatous optic neuropathy is the selective death of retinal ganglion cells associated with structural changes in the optic nerve head. Recent discoveries suggest a role for nitric oxide, glutamate, apoptosis, and others, in the pathophysiology of this neuropathy. These newer discoveries are addressed in this article.
Asunto(s)
Apoptosis/fisiología , Glaucoma de Ángulo Abierto/fisiopatología , Ácido Glutámico/fisiología , Factores de Crecimiento Nervioso/fisiología , Óxido Nítrico/fisiología , Enfermedades del Nervio Óptico/fisiopatología , Supervivencia Celular/fisiología , Glaucoma de Ángulo Abierto/metabolismo , Humanos , Fármacos Neuroprotectores/metabolismo , Enfermedades del Nervio Óptico/metabolismo , Células Ganglionares de la Retina/citologíaRESUMEN
PURPOSE: Glutamate antagonists can block ganglion cell death due to optic nerve crush. Although most investigators have focused on blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, we have chosen to evaluate the efficacy of blockade of the AMPA-kainate (KA) receptor in this experimental paradigm. METHODS: The optic nerves of rats were crushed, and ganglion cell survival was assessed. Groups of animals were treated with an NMDA antagonist, an AMPA-KA antagonist, or both. RESULTS: The AMPA-KA antagonist DNQX was more effective, although not additive in preserving retinal ganglion cells after optic nerve crush than the NMDA antagonist MK801. CONCLUSIONS: Activation of the AMPA-KA subtype of glutamate receptor may play a role in glutamate-mediated cell death after optic nerve crush.
Asunto(s)
Traumatismos del Nervio Óptico/metabolismo , Receptores AMPA/metabolismo , Receptores de Ácido Kaínico/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Células Ganglionares de la Retina/metabolismo , Animales , Supervivencia Celular/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Compresión Nerviosa , Fármacos Neuroprotectores/farmacología , Traumatismos del Nervio Óptico/patología , Traumatismos del Nervio Óptico/prevención & control , Quinoxalinas/farmacología , Ratas , Ratas Long-Evans , Receptores AMPA/antagonistas & inhibidores , Receptores de Ácido Kaínico/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Células Ganglionares de la Retina/efectos de los fármacos , Células Ganglionares de la Retina/patologíaRESUMEN
PURPOSE: Elevated levels of extracellular glutamate have been implicated in the pathophysiology of neuronal loss in both central nervous system and ophthalmic disorders, including glaucoma. This increase in glutamate may result from a failure of glutamate transporters (molecules that ordinarily regulate extracellular glutamate; E:xcitatory A:mino A:cid T:ransporter; EAAT). Elevated glutamate levels can also lead to alterations in glutamate receptor expression. It was hypothesized that selective blockade of glutamate transporters would be toxic to retinal ganglion cells. METHODS: Glutamate transporters were blocked either pharmacologically or with subtype-specific antisense oligonucleotides against EAAT1. Glutamate levels, transporter levels and ganglion cell survival were assayed. RESULTS: Pharmacological inhibition of glutamate transporters with either an EAAT2 specific inhibitor or a nonspecific inhibitor of all the subtypes of transporters was toxic to ganglion cells. Treatment with oligonucleotides against the glutamate transporter EAAT1 decreased the levels of expression of the transporter, increased vitreal glutamate, and was toxic to ganglion cells. CONCLUSIONS: These results demonstrate that normal function of EAAT1 and EAAT2 is necessary for retinal ganglion cell survival and plays an important role in retinal excitotoxicity. Manipulation of retinal glutamate transporter expression may become a useful tool in understanding retinal neuronal loss.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/antagonistas & inhibidores , Ácido Glutámico/metabolismo , Ácido Kaínico/análogos & derivados , Receptores de Neurotransmisores/antagonistas & inhibidores , Células Ganglionares de la Retina/patología , Cuerpo Vítreo/metabolismo , Transportadoras de Casetes de Unión a ATP/fisiología , Sistema de Transporte de Aminoácidos X-AG , Animales , Western Blotting , Muerte Celular , Cromatografía Líquida de Alta Presión , Cartilla de ADN/química , Ácidos Dicarboxílicos/farmacología , Transportador 2 de Aminoácidos Excitadores , Ácido Kaínico/farmacología , Inhibidores de la Captación de Neurotransmisores/farmacología , Oligonucleótidos Antisentido/farmacología , Pirrolidinas/farmacología , Ratas , Ratas Long-Evans , Receptores de Neurotransmisores/fisiologíaRESUMEN
Zinc-chelating agents, including ethambutol and its metabolite 2,2'(ethylenediamino)-dibutyric acid (EDBA) are toxic to retinal ganglion cells through a glutamate dependent mechanism. We explored whether such cell death was mediated through the caspase family of cysteine proteases. Retinal cultures were treated with EDBA alone, or EDBA plus a variety of known caspase inhibitors, and ganglion cell viability was assayed. EDBA killed 20-30% of ganglion cells. A general caspase inhibitor, BAF, prevented EDBA induced ganglion cell death. Specific inhibitors of caspase-3 and caspase-6 showed a similar ability to BAF in preventing EDBA mediated ganglion cell loss, whereas inhibitors of caspase-8 and caspase-9 were not able to rescue EDBA treated ganglion cells. A caspase-1,4 inhibitor was less effective than BAF. These studies show that a caspase mediated mechanism of apoptosis accents for a portion of EDBA mediated retinal ganglion cell death. This toxicity was mediated by downstream effector caspases, 3 and 6. Caspase inhibitors may prevent ganglion cell death secondary to ethambutol treatment.
Asunto(s)
Inhibidores de Caspasas , Quelantes/toxicidad , Inhibidores de Cisteína Proteinasa/farmacología , Inhibidores Enzimáticos/farmacología , Etambutol/toxicidad , Etilenodiaminas/toxicidad , Células Ganglionares de la Retina/efectos de los fármacos , Zinc/fisiología , Animales , Caspasa 3 , Caspasa 6 , Células Cultivadas , Fármacos Neuroprotectores/farmacología , Ratas , Ratas Long-Evans , Células Ganglionares de la Retina/citologíaRESUMEN
PURPOSE: Elevated levels of extracellular glutamate have been implicated in the pathophysiology of neuronal loss in both central nervous system and ophthalmic disorders, including glaucoma. This increase in glutamate may result from a failure of glutamate transporters, which are molecules that ordinarily regulate extracellular glutamate. Elevated glutamate levels can also lead to a perturbation in glutamate receptors. The hypothesis for the current study was that glutamate transporters and/or receptors are altered in human glaucoma. METHODS: Immunohistochemical analyses of human eyes with glaucoma and control eyes were performed to evaluate glutamate receptors and transporters. These molecules were also assayed in rat eyes injected with glial-derived neurotrophic factor (GDNF). RESULTS: Glaucomatous eyes had decreased levels of both the glutamate transporter, excitatory amino acid transporter (EAAT)-1, and the glutamate receptor subunit N-methyl-D-aspartate (NMDA)-R1. Eyes treated with GDNF had elevated levels of both EAAT1 and NMDAR1. CONCLUSIONS: The loss of EAAT1 in glaucoma may account for the elevated level of glutamate found in glaucomatous vitreous and lead to a compensatory downregulation of NMDAR1. Inasmuch as GDNF can increase levels of both EAAT1 and NMDAR1, it may be a useful therapeutic approach to restore homeostatic levels of these in glaucoma.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Glaucoma de Ángulo Cerrado/metabolismo , Glaucoma de Ángulo Abierto/metabolismo , Factores de Crecimiento Nervioso , Receptores de Glutamato/metabolismo , Retina/metabolismo , Anciano , Anciano de 80 o más Años , Sistema de Transporte de Aminoácidos X-AG , Animales , Regulación hacia Abajo , Factor Neurotrófico Derivado de la Línea Celular Glial , Ácido Glutámico/metabolismo , Humanos , Técnicas para Inmunoenzimas , Proteínas del Tejido Nervioso/farmacología , Fármacos Neuroprotectores/farmacología , Ratas , Receptores de N-Metil-D-Aspartato/metabolismo , Retina/efectos de los fármacosRESUMEN
In the mammalian retina, Thy-1, the most abundant mammalian neuronal surface glycoprotein, is found predominantly if not exclusively on retinal ganglion cells. We hypothesized that Thy-1 plays a significant role in retinal development. Neurite outgrowth of retinal ganglion cells from Thy-1(-) mice over multiple substrates was compared to that seen with wild-type controls. Adult mouse retinas were histologically compared between Thy-1(-) and three strains of Thy-1 positive mice. Thy-1(-) retinal ganglion cells had significantly less neurite outgrowth than controls. The inner nuclear, inner plexiform, ganglion cell and outer segment/pigment epithelium layers were thinner in Thy-1(-) retinae than in controls. Thy-1 appears to be critical for normal retinal development.
Asunto(s)
Retina/crecimiento & desarrollo , Antígenos Thy-1/fisiología , Animales , Técnicas In Vitro , Ratones , Ratones Endogámicos , Ratones Noqueados/genética , Neuritas/fisiología , Retina/citología , Células Ganglionares de la Retina/citología , Células Ganglionares de la Retina/metabolismo , Células Ganglionares de la Retina/fisiología , Antígenos Thy-1/genética , Antígenos Thy-1/metabolismoRESUMEN
Gene therapy has developed as a promising approach for therapy in a broad variety of conditions. Viral vectors have been developed that may replace a defective gene, prevent expression of a mutant gene, or deliver a protective gene and thereby delay cellular loss. Using adeno-associated virus containing green fluorescent protein (AAV-GFP) we were able to specifically transduce cells located in the inner retina and induce over-expression of GFP in adult rat retinae. The delivery and expression of GFP had no influence themselves on retinal ganglion cell survival. Administration of the reporter vector AAV-GFP provided retinal ganglion cells with slight but significant protection from intravitreal NMDA. This was a locally mediated phenomenon; greater protection was seen in regions with more transduced cells. Any evaluation of the efficacy of a putative viral vector should consider the possible protective or toxic effect of the native virus.
Asunto(s)
Dependovirus/genética , Agonistas de Aminoácidos Excitadores/toxicidad , Genes Reporteros/genética , Vectores Genéticos/genética , N-Metilaspartato/toxicidad , Animales , Supervivencia Celular , Proteínas Fluorescentes Verdes , Proteínas Luminiscentes/genética , Ratas , Ratas Sprague-Dawley , Células Ganglionares de la Retina/metabolismo , Transducción Genética/genéticaRESUMEN
Most therapy for glaucoma is directed at the management of the intraocular pressure (IOP). Conventional wisdom holds that excessive pressure within the eye leads to the ganglion cell loss/optic nerve damage seen in this disease. Both glutamate and elevated IOP can selectively damage the retinal ganglion cells in the mammalian eye. We have identified an elevated level of glutamate in the vitreous humor of glaucoma patients (27 microM as compared to 11 microM in the control population). This concentration of glutamate suffices--on its own--to kill retinal ganglion cells. It is plausible that the IOP may represent an initial insult that precipitates the production of excessive glutamate. Therefore, even if glutamate elevation is an epiphenomenon associated with the course of the disease, it may contribute to ganglion cell loss in humans. Lowering the IOP may slow down glutamate production, but if nothing is done to block the toxic effects of glutamate as well, visual loss may result despite excellent IOP control. If interventions can be found to retard the production or toxic effects of glutamate, it may be possible to slow glaucomatous visual loss.
Asunto(s)
Glaucoma/metabolismo , Ácido Glutámico/metabolismo , Enfermedades del Nervio Óptico/metabolismo , Animales , Apoptosis/efectos de los fármacos , Inhibidores Enzimáticos/uso terapéutico , Glaucoma/complicaciones , Glaucoma/tratamiento farmacológico , Humanos , Presión Intraocular , N-Metilaspartato/antagonistas & inhibidores , N-Metilaspartato/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Enfermedades del Nervio Óptico/tratamiento farmacológico , Enfermedades del Nervio Óptico/etiología , Células Ganglionares de la Retina/efectos de los fármacos , Células Ganglionares de la Retina/patología , Cuerpo Vítreo/metabolismoRESUMEN
The protooncogene bcl-2 can block neuronal death from both naturally occurring apoptosis and exogenous insults. bcl-2 is therefore a promising candidate for the prevention of excitotoxic neuronal death. Using an adeno-associated viral vector, we delivered the bcl-2 gene to the ganglion cell layer of the rat eye. We hypothesized that infection with bcl-2 would protect ganglion cells against excitotoxic cell death. However, retinal infection with bcl-2 increased ganglion cell susceptibility to both axonal injury and intravitreal NMDA. Our study--intended to explore the possibility of bcl-2 transduction as an in vivo therapeutic approach--revealed a deleterious effect of bcl-2 transduction.
Asunto(s)
Agonistas de Aminoácidos Excitadores/farmacología , Ganglios/efectos de los fármacos , N-Metilaspartato/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Animales , Supervivencia Celular/efectos de los fármacos , Dependovirus , Ganglios/citología , Expresión Génica , Terapia Genética/métodos , Vectores Genéticos , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , Ratas , Ratas Sprague-DawleyRESUMEN
PURPOSE: This study was undertaken to determine if retinal ganglion cell sensitivity to intraocular N-methyl-D-aspartate or kainate injections varied as a function of retinal location (eccentricity) or cell soma size. METHODS: Rat retinal ganglion cells surviving intraocular N-methyl-D-aspartate or intraocular kainate induced lesions were retrogradely labeled with horseradish peroxidase and analyzed using an image analysis system. Control animals were retrogradely labeled after vehicle injection only. Cell counting was performed at 48 sampling points over the entire retina and represented a total area of 1.92 mm2 per retina. RESULTS: Larger cells were more sensitive to kainate than to N-methyl-D-aspartate excitotoxicity; smaller cells more vulnerable to N-methyl-D-aspartate excitotoxicity. Further from the optic nerve, more smaller cells survived kainate administration. After N-methyl-D-aspartate administration, larger cells survived most, noticeably in the central retina. CONCLUSIONS: Our results suggest that loss of retinal ganglion cells after N-methyl-D-aspartate or kainate administration affects distinct populations of retinal ganglion cells, dependent upon soma size and retinal location. The mechanism by which certain classes of cells survive or succumb to such insults has yet to be determined.
Asunto(s)
Neurotoxinas/farmacología , Retina/fisiología , Células Ganglionares de la Retina/citología , Células Ganglionares de la Retina/efectos de los fármacos , Animales , Tamaño de la Célula/fisiología , Supervivencia Celular/efectos de los fármacos , Ácido Kaínico/farmacología , Masculino , N-Metilaspartato/farmacología , Ratas , Ratas Endogámicas , Retina/citología , Células Ganglionares de la Retina/fisiologíaRESUMEN
PURPOSE: To examine the effects of the local anesthetic, lidocaine, on rat retinal ganglion cells (RGC) in vitro and in a modified in vivo assay. METHODS: For in vitro experiments, RGC were dissociated from freshly harvested Long Evan's rat pup retinas. The RGC were incubated overnight with varying concentrations of lidocaine (0.5-12.0 mM). Surviving cells were assayed at 24 hours. In an in vivo assay, 7-day-old Long-Evans rat pups were anesthetized and 2 microl of lidocaine (final intraocular concentration: 0.03-15 mM) or vehicle was injected intravitreally. Intravitreal coinjection of nimodipine or MK801 (dizocilpine) were also performed in a subset of animals. A week after injection, rat pups were sacrificed and each retina removed, dissociated and plated separately. RGC survival was immediately assessed. Living RGC were identified on the basis of morphology and counted in a masked fashion. RESULTS: Lidocaine is toxic in a dose dependent fashion to RGC in vitro. Lower concentrations (0.5 mM and 1.0 mM) were non-toxic; 2.0, 6.0 and 12.0 mM lidocaine killed 25%, 88% and 99% of the RGC respectively. Intravitreal lidocaine was also toxic to RGC in a dose dependent fashion. Lidocaine concentrations of 3.0 mM, 7.5 mM and 15 mM killed 25%, 38% and 44% of the RGC. This effect was blocked by the simultaneous administration of either nimodipine or MK801. CONCLUSIONS: Lidocaine is toxic to RGC both in vitro and in vivo. This effect is blocked in vivo by the simultaneous administration of agents known to block glutamate mediated neuronal death, suggesting that excitotoxicity may be involved in this process.
Asunto(s)
Lidocaína/envenenamiento , Células Ganglionares de la Retina/efectos de los fármacos , Animales , Supervivencia Celular/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Lidocaína/antagonistas & inhibidores , Fármacos Neuroprotectores/farmacología , Nimodipina/farmacología , Ratas , Ratas Long-Evans , Células Ganglionares de la Retina/fisiologíaRESUMEN
Glaucoma can be defined as a disease in which one of the pathophysiological consequences of raised intra-ocular pressure is damage of the optic nerve, and subsequently the loss of retinal ganglion cells (RGCs). One of the main aims of modern glaucoma therapy is to alter the intraocular pressure, either surgically or pharmacologically. Recently it was shown that the vitreous of glaucoma patients contains increased levels of glutamate (27 microM as compared to 11 microM in controls). This concentration of glutamate is sufficient to induce retinal ganglion cell death. The rise in intraocular pressure is probably the initial insult, which enhances the increase or release of glutamate. Although the increase in intravitreal glutamate levels is an accompanying feature of glaucoma, it could contribute to the loss of retinal ganglion cells in humans itself. Therefore, despite efficient control of intra-ocular pressure, RGC's loss will continue resulting in further visual impairment, if the toxic effect of glutamate is not blocked. If it would be possible to understand the mechanism leading to excessive vitreous levels of glutamate in glaucoma or to block its toxic effects, then the resulting visual loss could be retarded. This review discusses various proposed mechanisms leading to intraocular glutamate toxicity and the role of neuroprotection in this disease. (Literature search by Medline).
Asunto(s)
Glaucoma/etiología , Glaucoma/patología , Animales , Glaucoma/metabolismo , HumanosRESUMEN
PURPOSE: There is growing evidence that the neuronal pathology seen with HIV-1 is mediated, at least in part, through an excitotoxic/free radical pathway. Nitric oxide (NO) plays a critical role in the nervous system, in both normal and pathologic states, and appears to be involved in a variety of excitotoxic pathways. Whether isoforms of nitric oxide synthase (NOS) are involved in gp120-mediated neuronal loss in the retina was therefore explored. METHODS: To determine which (if any) of the various isoforms of NOS are critical in gp120-mediated damage in the retina, neuronal NOS-deficient [nNOS(-/-)], endothelial NOS-deficient [eNOS(-/ -)], and immunologic NOS-deficient [iNOS(-/-)] mice were subjected to intravitreal injections of gp120. RESULTS: Retinal ganglion cells in the nNOS(-/-) mouse were relatively resistant to gp120, manifesting attenuation of gp120-induced injury compared with wild-type mice. The iNOS(-/-) and eNOS(-/-) mice were as susceptible to gp120 toxicity as control animals. NOS inhibitors were protective against this toxicity. CONCLUSIONS: The presence of nNOS is a prerequisite for the full expression of gp120-mediated loss in the retina; eNOS and iNOS do not appear to play a significant role.
Asunto(s)
Proteína gp120 de Envoltorio del VIH/toxicidad , VIH-1 , Óxido Nítrico Sintasa/fisiología , Células Ganglionares de la Retina/efectos de los fármacos , Animales , Recuento de Células , Muerte Celular/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Mutantes , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I , Óxido Nítrico Sintasa de Tipo II , Óxido Nítrico Sintasa de Tipo III , Nitroarginina/farmacología , Células Ganglionares de la Retina/enzimología , Células Ganglionares de la Retina/patologíaRESUMEN
PURPOSE: Muscarinic agents reduce intraocular pressure by enhancing aqueous outflow, probably by stimulating ciliary muscle contraction. However, pilocarpine is a well characterized neurotoxin and is widely used to generate animal seizure models. It was therefore investigated whether pilocarpine was also toxic to retinal ganglion cells. METHODS: Dissociated whole retinal preparations were prepared from postnatal day 16 to 19 rats. Retinal ganglion cells had been previously back-labeled with a fluorescent tracer. Retinal cells were incubated with pilocarpine, lithium, and inositol derivatives, and viability of the retrogradely labeled retinal ganglion cells was assayed after 24 hours. RESULTS: Pilocarpine was toxic to retinal ganglion cells in a dose-dependent fashion. This toxicity was potentiated by lithium and blocked by epi- and myo-inositol. CONCLUSIONS: Pilocarpine is toxic to retinal ganglion cells in a mixed culture assay. This toxicity appears to depend on the inositol pathway and is similar to its mode of action in other neurons. However, 0.4 mM pilocarpine (the lowest concentration that did not affect ganglion cell survival) is roughly 1000-fold higher than the vitreal concentration and 20-fold higher than the scleral concentration that can be obtained with topical administration of 2% pilocarpine in the rabbit eye.
Asunto(s)
Pilocarpina/toxicidad , Células Ganglionares de la Retina/efectos de los fármacos , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Inositol/farmacología , Litio/farmacología , Ratas , Ratas Long-EvansRESUMEN
The development of neuronal polarity and morphology is essential for a functioning nervous system. The present study was undertaken to explore whether blockade of specific channels alter neuronal morphology. Retinal ganglion cells were cultured in the presence of antagonists to NMDA, AMPA/kainate, L-, N-, P-, and Q-type voltage-dependent calcium channels (VDCCs). Five parameters were measured under these conditions: the number of neurites at the cell body, total neurite length, the length of the longest neurite, the number of branch points per neurite, and the diameter of the cell soma. Antagonists to NMDA and L-type VDCCs reduce the number of neurites at the cell body; antagonists to P- and Q-type VDCCs increase the number of neurites. Antagonists to the N-type VDCCs increase total neurite outgrowth, while antagonists to the NMDA and P-type channels reduce total neurite length. Antagonists to the NMDA and L-type channels increase the length of a single neurite, while decreasing the number of branch points; antagonists to the P- and Q-type VDCCs do essentially the opposite-increase the number of neurites, while decreasing the length of each. Blockade of one or more cation channels in developing retinal ganglion cells significantly perturbs neurite morphology. This study may help elucidate part of the role that cation channel signaling plays in neuritic development.
Asunto(s)
Canales de Calcio Tipo N , Canales de Calcio/fisiología , Neuritas/fisiología , Receptores de N-Metil-D-Aspartato/fisiología , Células Ganglionares de la Retina/química , Células Ganglionares de la Retina/citología , omega-Conotoxinas , 2-Amino-5-fosfonovalerato/farmacología , 6-Ciano 7-nitroquinoxalina 2,3-diona/farmacología , Animales , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio/análisis , Canales de Calcio Tipo L , Polaridad Celular/efectos de los fármacos , Tamaño de la Célula/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , Potenciales de la Membrana/efectos de los fármacos , Neuritas/química , Nimodipina/farmacología , Péptidos/farmacología , Ratas , Receptores de N-Metil-D-Aspartato/análisis , Células Ganglionares de la Retina/ultraestructura , Venenos de Araña/farmacología , Antígenos Thy-1/análisis , omega-Agatoxina IVA , omega-Conotoxina GVIARESUMEN
PURPOSE: Ethambutol is an essential medication in the management of tuberculosis. However, it can cause an optic neuropathy of uncertain etiology. Ethambutol toxicity was therefore studied in rodent retinal cells, and agents that might block its toxicity were considered. METHODS: The toxicity of ethambutol and related agents was evaluated in rodent retinal dissociated cell preparations and whole eyes. Calcium fluxes and mitochondrial function were evaluated by fluorescent and staining techniques. For in vivo assays, adult rats were administered oral ethambutol over a 3-month period. Cell survival was assessed by stereology. RESULTS: Ethambutol is specifically toxic to retinal ganglion cells in vitro and in vivo. Endogenous glutamate is necessary for the full expression of ethambutol toxicity, and glutamate antagonists prevent ethambutol-mediated cell loss. Ethambutol causes a decrease in cytosolic calcium, an increase in mitochondrial calcium, and an increase in the mitochondrial membrane potential. CONCLUSIONS: The visual loss associated with ethambutol may be mediated through an excitotoxic pathway, inasmuch as ganglion cells are rendered sensitive to normally tolerated levels of extracellular glutamate. Ethambutol perturbs mitochondrial function. Its toxicity may depend on decreased ATPase activity and mitochondrial energy homeostasis. Glutamate antagonists may be useful in limiting the side effects seen with ethambutol.